Category: FDA & Regulatory Policy

September 21, 2020

National Groups Call on U.S. Federal Health Agency Leaders to Stand Strong for Science Over Politics in the Fight Against COVID-19

The Alliance for Aging Research (Alliance) and 78 other national organizations representing patients, healthcare providers, and multi-stakeholder coalitions…
August 21, 2020

Alliance for Aging Research Submits Comments on Reauthorization of the Prescription Drug User Fee Act

      On Friday, August 21, the Alliance for Aging Research submitted feedback to the U.S. Food and…
February 12, 2020

Alliance for Aging Research Statement on FY2021 White House Proposed Budget

WASHINGTON, February 12, 2020 – The Alliance for Aging Research’s (Alliance) President and CEO Susan Peschin, MHS, has released the…
December 21, 2019

Alliance for Aging Research Statement on the FY2020 Budget

WASHINGTON, December 21, 2019 – The Alliance for Aging Research’s (Alliance) President and CEO Susan Peschin, MHS, has released the…
December 13, 2019

Alliance for Aging Research Congratulates Dr. Stephen Hahn on Appointment to FDA Commissioner

      Yesterday the Senate confirmed Dr. Stephen Hahn as the Commissioner of the U.S. Food and Drug…
November 19, 2019

Alliance for Aging Research Supports the Nomination of Dr. Stephen Hahn for FDA Commissioner

On November 18, Alliance for Aging Research President and CEO Sue Peschin, MHS, sent a letter to the Senate on…
March 13, 2019

Alliance for Aging Research Statement on FY 2020 White House Proposed Budget

Alliance for Aging Research President and CEO Susan Peschin, MHS, issued the following statement in response to the White House’s…
June 15, 2018

ACT-AD Coalition Letter on FDA Early Alzheimer’s Disease Guidance

The majority of clinical trials conducted in Alzheimer’s disease have been for patients who received a definitive diagnosis after becoming…
July 12, 2017

Five Questions (and Answers) about the FDA Reauthorization Act of 2017

Right now, the U.S. Congress is considering the FDA Reauthorization Act of 2017 , legislation that will reauthorize the pharmaceutical, medical device, generic drug, and biosimilar user fee agreements. The five-year deal is one of the most important health care bills Congress will vote on this year.
May 23, 2017

Alliance Statement on FY 2018 White House Proposed Budget on NIH, FDA, CDC

Alliance President and CEO Susan Peschin, MHS, has issued the following statement in response to the White House’s proposed Fiscal Year 2018 budget.